Eisai Plots A Meticulous Path To Medicare Coverage For Lecanemab
US Exec Ivan Cheung Expects ‘More Open Access’ To Drug
Ivan Cheung, Eisai’s US CEO, explains the ‘question-by-question’ the company is taking to convince the Centers for Medicare and Medicaid Services that its Phase III Clarity AD results in Alzheimer’s offer the ‘high level of evidence’ needed for smooth reimbursement of lecanemab.
